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frequency of ophthalmologist visits, probability of
surgery and total costs. The user can specify country-
speciﬁc treatment strategies, therapy discontinuation, sur-
gical rates, practice patterns and costs. RESULTS: The
key challenges included: selection of a disease outcome
that was relevant to current clinical practice; choice of
time horizon; incorporation of therapy discontinuation;
reﬂection of diversity in treatment options; and consider-
ation of variability in patient response. CONCLUSIONS:
Modeling the clinical and economic impacts of glaucoma
treatment involve challenges shared with other chronic
diseases where the deﬁnition of treatment success is
patient-speciﬁc. The model offers insights into accommo-
dating patient-speciﬁc variability through the use of per-
sistence distributions from actual clinical practice. The
model provides a clinically relevant tool for decision-
makers and clinicians to assess management strategies for
glaucoma.
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OBJECTIVE: To develop a generic decision-analytic
model for the evaluation of long-term clinical and eco-
nomic consequences of interventions in patients with
Parkinson’s disease (PD) which can be applied to differ-
ent research questions, interventions, and outcomes, 
and is based on (untreated) biological progression.
METHODS: We developed a Markov model, in which a
hypothetical cohort of patients moves through health
states reﬂecting patient characteristics that are observed
under treatment (Hoehn and Yahr “on” state [HYon])
and would be observed in the absence of treatment
(Hoehn and Yahr “off” state [HYoff]). We used HYoff
I–V s as Markov states, because those reﬂect underlying
biologic progression of PD. Interventions: diagnostic or
treatment strategies in PD patients such as Levodopa,
dopamine agonists, or other anti-parkinsonian drugs as
well as surgical therapies such as deep brain stimulation.
Data: Transition probabilities for HYoff states were
derived from the literature. The distribution of HYon 
was modeled conditional on HYoff using studies that
report both characteristic. Complications were modeled
conditional on HYon using data from a registry estab-
lished by the “Competence Network Parkinson Disease”.
Utilities, and costs were modeled conditional on HYon
and presence of complication. Mortality is a function 
of age- and gender-speciﬁc background mortality and PD-
speciﬁc mortality Time horizon: lifetime with annual
cycle length. RESULTS: Remaining (quality-adjusted) 
life expectancy, direct costs, and incremental cost-
effectiveness ratios. Further outcomes comprise clinical
events or complications such as motor complications,
dementia, depression, and hallucinations. In addition,
complication-free survival, time in HYoff and HYon
states, and UPDRS scores were modeled as additional
outcomes. Perspective: societal and third party payer. 
Sensitivity analysis: 1-way and multiway. An interactive
interface allows to model different settings or countries.
CONCLUSIONS: In contrast to formerly published
models, this generic PD model has the ability to consider
multiple interventions and outcomes and to switch
between outcomes depending on which outcomes are
reported in a clinical trial.
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OBJECTIVES: The most wide-spread acid-related disor-
ders are peptic ulcer disease (PUD) and gastroesophageal
reﬂux (GERD). The literature indicates that during past
years PUD had been diagnosed less frequently, whereas
GERD had been diagnosed more often. Our study aimed
at modelling the prevalence of PUD and GERD using
claims data of a major sickness fund. The second aim was
to quantify the drug expenditures for acid-related disor-
ders and to analyse the outcomes of eradication therapy
under non-interventional routine treatment conditions.
METHODS: On the basis of prescription records from
2000 and 2001, insured persons were classiﬁed as GERD
or PUD patients according to typical prescription pat-
terns, to the diagnoses of sick leave periods and hospi-
talisations. According to this classiﬁcation, the prevalence
of acid-related disorders was modelled. Outcomes were
analysed by comparing hospitalisations, sick leave
periods and costs in groups with and without eradication
therapy. RESULTS: From a total of 1,408,902 insured
persons 134,759 had at least one antacid prescription.
With regard to the deﬁned prescription patterns we esti-
mated a 2-year treatment prevalence of 3.93% and
3.77% for PUD and GERD, respectively. Within the 2-
year period, drug expenditures for the treatment of acid-
related disorders added up to €5.9 and €8.1 million,
respectively. For 5,926 out of 41,301 people assumed to
suffer from PUD, an eradication therapy could be
detected. In groups without eradication therapy the risk
for hospitalisation or sick leave periods was twice as high
as in groups with eradication therapy. Hospitalisation
costs were considerably higher, too. CONCLUSIONS:
Although eradication therapy was found to reduce the
risk for hospitalisation, sick leave periods and costs, this
therapeutic approach was practised only for a minor pro-
portion of patients suffering from PUD. Our ﬁndings
suggest that there is still room for diagnostic and thera-
peutic improvement in the management of acid-related
disorders.
